These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3934387)

  • 1. New antihistaminic N-heterocyclic 4-piperidinamines. 3. Synthesis and antihistaminic activity of N-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-2-amines.
    Janssens F; Torremans J; Janssen M; Stokbroekx RA; Luyckx M; Janssen PA
    J Med Chem; 1985 Dec; 28(12):1943-7. PubMed ID: 3934387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
    Janssens F; Torremans J; Janssen M; Stokbroekx RA; Luyckx M; Janssen PA
    J Med Chem; 1985 Dec; 28(12):1934-43. PubMed ID: 3934386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antihistaminic N-heterocyclic 4-piperidinamines. 1. Synthesis and antihistaminic activity of N-(4-piperidinyl)-1H-benzimidazol-2-amines.
    Janssens F; Torremans J; Janssen M; Stokbroekx RA; Luyckx M; Janssen PA
    J Med Chem; 1985 Dec; 28(12):1925-33. PubMed ID: 4068010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound.
    Van Wauwe J; Awouters F; Neimegeers CJ; Janssens F; Van Nueten JM; Janssen PA
    Arch Int Pharmacodyn Ther; 1981 May; 251(1):39-51. PubMed ID: 6114717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of E-4716, a new antihistaminic with antiallergic properties, on chemical mediators induction of immunologic reactions.
    Gutiérrez B; Dordal A; Fort M; Galicia J; Farré AJ
    Methods Find Exp Clin Pharmacol; 1996; 18(6):397-406. PubMed ID: 8892269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist.
    Corcóstegui R; Labeaga L; Innerárity A; Berisa A; Orjales A
    Drugs R D; 2006; 7(4):219-31. PubMed ID: 16784247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihistaminic/antiallergic activity of 2-dialkylaminoalkylthio(oxy)-1-substituted benzimidazoles: evaluation "in vitro" and "in vivo".
    Dini S; Caselli GF; Basilico C; Lavezzo A; Giani R
    Agents Actions; 1990 Apr; 30(1-2):174-7. PubMed ID: 1695440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacological profile of a specific, safe, effective and non-sedative anti-allergic, astemizole.
    Niemegeers CJ; Awouters F; Janssen PA
    Agents Actions; 1986 Apr; 18(1-2):141-4. PubMed ID: 2873722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiallergic effects of major metabolites of astemizole in rats and guinea pigs.
    Kamei C; Mio M; Izushi K; Kitazumi K; Tsujimoto S; Fujisawa K; Adachi Y; Tasaka K
    Arzneimittelforschung; 1991 Sep; 41(9):932-6. PubMed ID: 1724600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
    Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine.
    Barnett A; Iorio LC; Kreutner W; Tozzi S; Ahn HS; Gulbenkian A
    Agents Actions; 1984 Jun; 14(5-6):590-7. PubMed ID: 6236679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo studies of the non-sedating antihistamine epinastine.
    Fügner A; Bechtel WD; Kuhn FJ; Mierau J
    Arzneimittelforschung; 1988 Oct; 38(10):1446-53. PubMed ID: 2461715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type.
    Plazzi PV; Mor M; Bordi F; Silva C; Rivara S; Caretta A; Ballabeni V; Impicciatore M; Vitali T
    Farmaco; 1997 May; 52(5):295-302. PubMed ID: 9274000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New histamine H(3)-receptor ligands of the proxifan series: imoproxifan and other selective antagonists with high oral in vivo potency.
    Sasse A; Sadek B; Ligneau X; Elz S; Pertz HH; Luger P; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2000 Aug; 43(17):3335-43. PubMed ID: 10966752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacology of astemizole (Hismanal) a non-sedating H1 antihistaminic].
    Niemegeers CJ
    Z Hautkr; 1985; 60 Suppl 1():14-22. PubMed ID: 2581383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-(Indolyl-3)-1-(benzimidazolonylalkyl)-piperidines, a novel group of potential antiallergy compounds.
    Freter K; Fuchs V; Barsumian E; Oliver JT
    Arzneimittelforschung; 1985; 35(1A):272-6. PubMed ID: 2580540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
    Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
    J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
    Lapierre JM; Eathiraj S; Vensel D; Liu Y; Bull CO; Cornell-Kennon S; Iimura S; Kelleher EW; Kizer DE; Koerner S; Makhija S; Matsuda A; Moussa M; Namdev N; Savage RE; Szwaya J; Volckova E; Westlund N; Wu H; Schwartz B
    J Med Chem; 2016 Jul; 59(13):6455-69. PubMed ID: 27305487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.